Synthesis, study of antileishmanial and antitrypanosomal activity of imidazo pyridine fused triazole analogues. Issue 63 (19th October 2020)

• Record Type: Journal Article
• Authors: Nandikolla, Adinarayana; Srinivasarao, Singireddi; Karan Kumar, Banoth; Murugesan, Sankaranarayanan; Aggarwal, Himanshu; Major, Louise L.; Smith, Terry K.; Chandra Sekhar, Kondapalli Venkata Gowri
• Is Part Of: RSC advances. Volume 10:Issue 63(2020)
• Page Start: 38328
• Page End: 38343
• Publication Date: 2020-10-19
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d0ra07881f
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Thirty-five novel 1, 2, 3-triazole analogues of imidazo-[1, 2- a ]-pyridine-3-carboxamides were designed, synthesized and evaluated for in vitro antileishmanial and antitrypanosomal activity against L. major and T. brucei parasites, respectively. Abstract : Four groups, thirty-five compounds in total, of novel 1, 2, 3-triazole analogues of imidazo-[1, 2- a ]-pyridine-3-carboxamides were designed and synthesized using substituted pyridine, propargyl bromide, 2-azidoethyl 4-methyl benzenesulfonate and substituted acetylenes. These compounds were characterized using 1 H NMR, 13 C NMR, LCMS and elemental analyses and a crystal structure was obtained for one of the significantly active compounds, 8f . All the synthesized and characterized compounds were screened in vitro for antileishmanial and antitrypanosomal activity against Leishmania major and Trypanosoma brucei parasites, respectively. Among the tested analogues, five compounds (8d, 8f, 8j, 10b and 10d ) exhibited significant antileishmanial activity while three compounds (10b, 11a and 11b ) showed substantial activity against T. brucei parasite. In silico ADME prediction studies depicted that the essential compounds obeyed Lipinski's rule of five. The predicted in silico toxicity profile suggested that the tested compounds would be non-toxic, which was confirmed experimentally by the lack of cytotoxicity against HeLa cells. Finally, a molecular docking study was also performed, for 10d the most active antileishmanial compound, to study its putative binding pattern at the active site of the selected leishmanial trypanothione reductase target.